CAR T Cell Therapy Market To Reach USD 39.9 Billion By 2032, Says DataHorizzon Research [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Fort Collins, Colorado, May 07, 2024 (GLOBE NEWSWIRE) -- The growing prevalence of cancer is a prominent factor in the development of CAR T Cell therapy. The increasing prevalence of cancer worldwide is a significant driving factor for the CAR T Cell Therapy market . According to the World Health Organization, cancer is a leading cause of death globally, with an estimated 19.3 million new cases and 10 million cancer-related deaths in 2020. As the incidence of cancer continues to rise, the demand for effective and targeted therapies like CAR T Cell Therapy is expected to grow. Moreover, the limitations of conventional cancer treatments, such as chemotherapy and radiation, have led to a greater focus on personalized and immune-based therapies, further driving the adoption of CAR T Cell Therapy. Recent advancements in genetic engineering and cell therapy technologies have played a crucial role in the development and growth of the CAR T Cell Therapy market. Innovations in gene edit
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- ArriVent Appoints John Hohneker, M.D., to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- ‘The 2024 Great Unbossing' Trending Among Middle Manager Careers In The Workplace [Forbes]Forbes
- Julius Bär Gruppe Leads Trio Of Swiss Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents [Yahoo! Finance]Yahoo! Finance
- Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- NVS's page on the SEC website